BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

206 related articles for article (PubMed ID: 33165815)

  • 1. Activities and polymorphisms of MMP-2 and MMP-9, smoking, diabetes and risk of prostate cancer.
    Kiani A; Kamankesh M; Vaisi-Raygani A; Moradi MR; Tanhapour M; Rahimi Z; Elahi-Rad S; Bahrehmand F; Aliyari M; Aghaz F; Mozafari H; Rezvani N; Haghnazari L; Pourmotabbed T
    Mol Biol Rep; 2020 Dec; 47(12):9373-9383. PubMed ID: 33165815
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Impact of MMP-3 and TIMP-3 gene polymorphisms on prostate cancer susceptibility in North Indian cohort.
    Srivastava P; Kapoor R; Mittal RD
    Gene; 2013 Nov; 530(2):273-7. PubMed ID: 23872201
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Matrix metalloproteinases as diagnostic (MMP-13) and prognostic (MMP-2, MMP-9) markers of prostate cancer.
    Morgia G; Falsaperla M; Malaponte G; Madonia M; Indelicato M; Travali S; Mazzarino MC
    Urol Res; 2005 Feb; 33(1):44-50. PubMed ID: 15517230
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The Behavior of MMP-2, MMP-7, MMP-9, and Their Inhibitors TIMP-1 and TIMP-2 in Adenoma-Colorectal Cancer Sequence.
    Barabás L; Hritz I; István G; Tulassay Z; Herszényi L
    Dig Dis; 2021; 39(3):217-224. PubMed ID: 32961536
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Metalloproteinases MMP-2 and MMP-9 and their inhibitors TIMP-1 and TIMP-2 levels in children and adolescents with type 1 diabetes].
    Florys B; Głowińska B; Urban M; Peczyńska J
    Endokrynol Diabetol Chor Przemiany Materii Wieku Rozw; 2006; 12(3):184-9. PubMed ID: 17020653
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Matrix metalloproteinases in premature coronary atherosclerosis: influence of inhibitors, inflammation, and genetic polymorphisms.
    Nanni S; Melandri G; Hanemaaijer R; Cervi V; Tomasi L; Altimari A; Van Lent N; Tricoci P; Bacchi L; Branzi A
    Transl Res; 2007 Mar; 149(3):137-44. PubMed ID: 17320799
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Imbalanced circulating matrix metalloproteinases in polycystic ovary syndrome.
    Gomes VA; Vieira CS; Jacob-Ferreira AL; Belo VA; Soares GM; Fernandes JB; Ferriani RA; Tanus-Santos JE
    Mol Cell Biochem; 2011 Jul; 353(1-2):251-7. PubMed ID: 21437624
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Serum matrix metalloproteinases MMP-2 and MMP-9 and metalloproteinase tissue inhibitors TIMP-1 and TIMP-2 in diabetic nephropathy.
    Rysz J; Banach M; Stolarek RA; Pasnik J; Cialkowska-Rysz A; Koktysz R; Piechota M; Baj Z
    J Nephrol; 2007; 20(4):444-52. PubMed ID: 17879211
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Association of Matrix Metalloproteinase-2 (MMP-2) and MMP-9 Promoter Polymorphisms, Their Serum Levels, and Activities with Coronary Artery Calcification (CAC) in an Iranian Population.
    Elahirad S; Elieh Ali Komi D; Kiani A; Mohammadi-Noori E; Vaisi-Raygani A; Mozafari H; Bahrehmand F; Saidi M; Toupchi-Khosroshahi V; Salehi N
    Cardiovasc Toxicol; 2022 Feb; 22(2):118-129. PubMed ID: 34731407
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Matrix metalloproteinases and their tissue inhibitors in serum and cerebrospinal fluid of patients with amyotrophic lateral sclerosis.
    Niebroj-Dobosz I; Janik P; Sokołowska B; Kwiecinski H
    Eur J Neurol; 2010 Feb; 17(2):226-31. PubMed ID: 19796283
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Association analysis of genetic polymorphisms and expression levels of selected genes involved in extracellular matrix turnover and angiogenesis with the risk of age-related macular degeneration.
    Oszajca K; Szemraj M; Szemraj J; Jurowski P
    Ophthalmic Genet; 2018 Dec; 39(6):684-698. PubMed ID: 30289322
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Circulating matrix metalloproteinases and their endogenous inhibitors in patients with erectile dysfunction.
    Muniz JJ; Lacchini R; Belo VA; Nobre YT; Tucci S; Martins AC; Tanus-Santos JE
    Int J Impot Res; 2012; 24(1):38-43. PubMed ID: 21918531
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Imbalanced matrix metalloproteinase-9 and tissue inhibitor of metalloproteinase-1 activities in patients with thromboangiitis obliterans.
    Dellalibera-Joviliano R; Jacob-Ferreira AL; Joviliano EE; Tanus-Santos JE; Evora PR
    Vasc Med; 2012 Apr; 17(2):73-8. PubMed ID: 22402936
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evaluation of Matrix Metalloproteinase-2 (MMP-2) and -9 (MMP-9) and Their Tissue Inhibitors (TIMP-1 and TIMP-2) in Plasma from Patients with Neurodegenerative Dementia.
    Tuna G; Yener GG; Oktay G; İşlekel GH; Kİrkalİ FG
    J Alzheimers Dis; 2018; 66(3):1265-1273. PubMed ID: 30412498
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Association of Matrix Metalloproteinase-2 (MMP-2) and MMP-9 Promoter Variants, Their Serum Levels, and Activities with Aortic Valve Calcification (AVC) in a Population from Western Iran.
    Heidari Moghadam R; Babajani F; Karami A; Elieh-Ali-Komi D; Hoseini F; Salehi N; Elahirad S; Mohammadi-Noori E; Mohammadi H; Kiani A
    Genet Test Mol Biomarkers; 2024 Jun; 28(6):223-232. PubMed ID: 38708584
    [No Abstract]   [Full Text] [Related]  

  • 16. Diabetes may affect the expression of matrix metalloproteinases and their inhibitors more than smoking in chronic periodontitis.
    Bastos MF; Tucci MA; de Siqueira A; de Faveri M; Figueiredo LC; Vallim PC; Duarte PM
    J Periodontal Res; 2017 Apr; 52(2):292-299. PubMed ID: 27363729
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Expression of matrix metalloproteinase-2 and -9 and their inhibitors, tissue inhibitor of metalloproteinase-1 and -2, in primary cultures of human prostatic stromal and epithelial cells.
    Wilson MJ; Sellers RG; Wiehr C; Melamud O; Pei D; Peehl DM
    J Cell Physiol; 2002 May; 191(2):208-16. PubMed ID: 12064464
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Decreases in plasma MMP-2/TIMP-2 and MMP-9/TIMP-1 ratios in uremic patients during hemodialysis.
    Lu LC; Yang CW; Hsieh WY; Chuang WH; Lin YC; Lin CS
    Clin Exp Nephrol; 2016 Dec; 20(6):934-942. PubMed ID: 26711243
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Matrix metalloproteinase (MMP)-2 genetic variants modify the circulating MMP-2 levels in end-stage kidney disease.
    Marson BP; Lacchini R; Belo V; Dickel S; da Costa BP; Poli de Figueiredo CE; Tanus-Santos JE
    Am J Nephrol; 2012; 35(3):209-15. PubMed ID: 22302011
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Serum matrix metalloproteinases -2, -9 and tissue inhibitors of metalloproteinases -1, -2 in lung cancer--TIMP-1 as a prognostic marker.
    Ylisirniö S; Höyhtyä M; Turpeenniemi-Hujanen T
    Anticancer Res; 2000; 20(2B):1311-6. PubMed ID: 10810441
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.